About Us

Text Size A A

E-Mail to a Friend

secret  Click to Play Audio

Promising Breast Cancer Vaccine Trial for HER2-Positive Breast Cancer Patients

Contact Information:
Dean Forbes

Download Press Release:

08-03-2011 Ampligen Press Release (39kb)
SCCA Ampligen trial press release

For Immediate Release
Aug. 3, 2011


SEATTLE – Seattle Cancer Care Alliance and University of Washington researcher Lupe G. Salazar, M.D., is enrolling patients with HER2-positive breast cancer for a study using a HER2 vaccination with Ampligen as an adjuvant (substance added to a cancer vaccine to boost its effectiveness).

This is a Phase I-II randomized, two-stage study for breast cancer patients being conducted by Salazar and the University of Washington Tumor Vaccine Group (TVG). In the first study stage, patients will be randomized into one of four treatment groups. Patients in each group will receive the HER-2/neu peptide vaccine combined with one of four Ampligen doses.

In the second study stage, patients will be randomized into one of two treatment arms. Arm I patients will receive the HER-2/neu peptide vaccine with GM-CSF (Granulocyte-macrophage Colony Stimulating Factor), a standard adjuvant.

Arm II patients will receive the HER-2/neu peptide vaccine with GM-CSF and Ampligen (the Ampligen dose with the highest immune response and lowest toxicity defined in stage I will be used).

"The goal is to find safe, new adjuvants that can be added to cancer vaccines to induce strong, long-lasting immune responses capable of preventing breast cancer relapse after standard therapy,” Salazar said.

For more information about this study or to enroll, go to www.seattlecca.org/clinical-trials/breastcancer-NCT01355393.cfm or contact Stephanie Parker (866) 932-8588, TVGTrial@uw.edu.

About Seattle Cancer Care Alliance – 10 Years, Thousands of Lives Saved
Every day, the goal of Seattle Cancer Care Alliance is to turn cancer patients into cancer survivors. SCCA unites the adult and pediatric cancer-care programs of Fred Hutchinson Cancer Research Center, UW Medicine and Seattle Children’s. Together they comprise the only National Cancer Institute-designated comprehensive cancer center in six states, from Washington to the Dakotas. A major focus of SCCA is to speed the transfer of new diagnostic and treatment techniques from the research setting to the patient bedside. Patients receive the latest research-based cancer therapies as well as cutting-edge treatments. SCCA has three clinical-care sites: an outpatient clinic on the Hutchinson Center campus, a pediatric-inpatient unit at Children’s and an adult-inpatient unit at UW Medical Center. SCCA celebrates its 10th anniversary in 2011. For more information visit www.seattlecca.org

Media Contact:
Dean Forbes

Related Diseases